Sara Cherry, PhD
John W. Eckman Professor of Medical Science
Professor of Microbiology
Professor of Microbiology in Biochemistry and Biophysics
Scientific Director, High-Throughput Screening Core
Director, Program for Chemogenomic Discovery
Perelman School of Medicine at the University of Pennsylvania
Contact InformationPerelman School of Medicine at the University of Pennsylvania
Department of Pathology and Laboratory Medicine
Stemmler Hall, Rm. 472A
3450 Hamilton Walk
Philadelphia, PA 19104
Tel: 215-746-2384
Email: cherrys@pennmedicine.upenn.edu
Specialty Division
Cancer and Immunobiology
Research Expertise
Research Interests:
Genetic and mechanistic studies of viral-host interactions
Key Words:
Emerging virus, coronavirus, arbovirus, genomics, antivirals, genetics, Drosophila, innate, immunity
Description of Research:
The Cherry Lab is interested in genetic and mechanistic studies of viral-host interactions. The Lab uses chemical and genetic screening technologies to explore the interface between viruses and hosts. The laboratory performs a wide array of cell-based screens in human and insect cells studying emerging viruses with a historical focus on arthropod-borne viruses such as chikungunya and zika virus. Innate immunity is the first line of defense against viruses and much of the recognition of these invaders is at the level of nucleic acid recognition. Arthropod-borne human viruses are RNA viruses and we are examining the role of RNA binding proteins and the RNA decay machinery in innate antiviral defense against these viruses in human cells. Since these viruses can infect diverse tissues we are also exploring antiviral innate signaling activities in distinct cell types including neurons, endothelial cells, and myeloid lineages. We have demonstrated cell-type specific immune pathways. Moreover, as these arthropod-borne viruses infect the vector insect enterically, we use Drosophila to model these intestinal infections to explore the role of the microbiota and innate defenses in the gut in the response to enteric arboviral infections. Projects include understanding how dysbiosis impacts susceptibility and discovering the bacterial products that impact infection. The recent coronavirus pandemic has led us to use our screening technologies to identify drugs that have antiviral activity as well as the role of innate pathways in controlling infection of SARS-CoV-2 in respiratory cells. The laboratory has many projects exploring diverse areas of viral-host interactions and innate immunity.
In addition, the Cherry lab has extended their studies to precision medicine and oncology. In collaborations across UPENN including the high-throughput screening core, oncologists, and pathologists the lab has developed a pipeline to test patient tumor cells for sensitivities to chemotherapeutics in an effort to personalize treatments. Work in acute myelogenous leukemia has demonstrated clear differences in patient responses and has uncovered new dependencies that will be translated into new treatment strategies in the future.
Rotation Projects:
Interested students can work on diverse aspects of viral-host interactions of emerging viruses from arboviruses to coronaviruses. They can involve the study of factors that facilitate infection such as entry pathways or the study of innate immune mechanisms at play.
Lab Personnel: | ||||
Benjamin Gabriel | Senior Research Investigator | Iulia Tapescu | Graduate Student - BMB Grad Student | |
Kasirajan Ayyanathan | Senior Research Investigator | Rachel Braun | Graduate Student - BMB Grad Student | |
Marie Arvidson | Research Specialist A | Tamanna Srivastava | Graduate Student - BMB Grad Student | |
Alex Huber | Research Specialist B | Jorge Acuña | Graduate Student - CAMB Grad Student | |
Jesse Hulahan | Research Specialist C | Kaeri Martinez | Graduate Student - CAMB Grad Student | |
Jesse Miller | Research Specialist C | Mark Dittmar | Graduate Student - CAMB Grad Student | |
Beth Gordesky Gold | Research Specialist D | Trevor Griesman | Graduate Student - CAMB Grad Student | |
Swechha Mainali Pokharel | Research Specialist D | Ashley Abraham | Undergraduate | |
Guangda Shi | Postdoctoral Researcher | Lara Hairapetian | Undergraduate | |
Jaeseung Lee | Postdoctoral Researcher | Oleksandr Zginnyk | Undergraduate | |
Max Ferretti | Postdoctoral Researcher | |||
Priyanka Bhakt | Postdoctoral Researcher | |||
Steven Miller | Postdoctoral Researcher | |||
Zienab Etwebi | Postdoctoral Researcher |
Itmat Expertise:
Research in the Cherry lab is aimed at identifying cellular factors that regulate viral pathogenesis, including factors hijacked by viruses for replication and innate anti-viral mechanisms used by the host to combat the invader. We study a number of arthropod-borne RNA viruses, including flaviviruses such as West Nile virus, dengue virus and the newly emerging Zika virus. We are also studying the alphaviruses including Sindbis and Chikungunya virus as well as the bunyaviruses Rift Valley Fever virus and La Crosse virus. These are the three major families of viruses that are important human pathogens transmitted by mosquitoes to humans.
To identify cellular factors that play important roles in infection we are taking a genetic approach and screening for factors that impact viral replication. We model the vector biology using the genetically tractable model organism Drosophila. This allows us to use a wide-variety of techniques including both high-throughput RNA interference screens in cell culture, and forward genetic screens in animals to identify genes that impact the viral life cycle. We also use human cell culture models to study the infection of mammals performing cell-based screens and mechanistic studies. Combining forward genetics and functional genomics comparing and contrasting between viruses and hosts allows us to use these unbiased and global methodologies to identify many important and novel host factors that modulate virus-host interactions. Through these studies we have discovered a large number of new factors and pathways involved from new pattern recognition receptors and nucleic acid sensing to previously unknown factors required for viral entry. In addition, our recent studies have uncovered new facets of intestinal immunity demonstrating a role for the microbiota in antiviral defense.
Graduate Groups
Biochemistry and Molecular Biophysics
Cell and Molecular Biology
Genomics and Computational Biology
Immunology
Pharmacology
Education
BS (Chemistry), University of California Berkeley, 1994
PhD (Biology), Massachusetts Institute of Technology, 2000
Specialty Certification
Postgraduate Training
Postdoctoral Fellow, Department of Genetics, Harvard Medical School, 2000-05
Awards and Honors
NIH Training Grant Appointment, 1994
NIH-NIAID NRSA Fellowship, 2000
MARCE Career Development Grant, 2007
Faculty of 1000 Medicine, Biodefense Section, 2008
BWF Investigator in the Pathogenesis of Infectious Diseases, 2011
Montague Award, 2013
Penn Fellow, 2014
John Morgan Society, 2017
Fellow, American Academy of Microbiology, 2018
Board Member, Society for Functional Precision Medicine, 2018-2021
Stanley Cohen Award, 2019
Matis Family Award, 2021
Fellow, American Association for the Advancement of Science (AAAS), 2022
Memberships and Professional Organizations
Genetics Society of America, 2002-present
-------- Larry Sandler Award Committee, 2013
-------- Drosophilia Research Conference, Chair, 2014
American Society of Virology, 2005-present
-------- Workshop Convener, 2008, 2014
-------- Program Planning Committee, Abstract Selection, 2009-13
Immunology Graduate Group (IGG), University of Pennsylvania, 2005-present
-------- Executive Committee, 2014-present
-------- Student Advising, Co-Director, 2014-present
Cell and Molecular Biology Graduate Group (CAMB), University of Pennsylvania, 2006-present
-------- CAMB MVP Graduate Group, Executive Committee, 2015-present
Genomics and Computational Biology Graduate Group, University of Pennsylvania, 2006-present
American Association of Immunology, 2009-present
-------- Major Symposium Organizer, 2019-present
Biochemistry and Molecular Biophysics Graduate Group, University of Pennsylvania, 2011-present
MRC-Medical Research Council, Grant Reviewer, 2012
European Research Council, Grant Reviewer, “Ideas,” 2013
NIH
-------- NIH Study Section, NIH/NIAID (AITRC), Ad Hoc, 2007
-------- NIH Roadmap CPSF Workshop, Chair, 2008
-------- NIH Study Section, NHGRI ZHG1HGR-M, 2011
-------- NIH Study Section, NIAID ZAI1 RRS, 2012
-------- NIH Study Section, NIGMS ZRG1 CB-R, Ad Hoc, 2012
-------- NIH Study Section, NIAID VIRB, Ad Hoc, 2013-14; Member 2014-present
-------- MPSCoRe Working Group, 2021-present
National Science Foundation (NSF) Study Section, Ad Hoc, 2010, 2013, 2015
DOD DTRA Study Section, 2011
American Association for the Advancement of Science (AAAS), 2013-present
American Society for Microbiology (ASM), 2013-present
Keystone Symposia
-------- Meeting, Abstract Selection, Meeting Convener, 2013-14
-------- Inaugural Organizer, “Intrinsic Defenses and Counterdefenses,” 2018
University of Pennsylvania Biomedical Graduate Studies, Biostatistics Curriculum Committee, 2013-14
Abramson Cancer Center, Penn Medicine, 2017-present
Viruses International Conferences, Organizer, 2018
International Advisory Board (IAB) for Perelman School of Medicine at the University of Pennsylvania
-------- CRISPR Core, 2019-present
-------- Electron Microscopy Core, 2019-present
University of Pittsburgh, Center for Vaccines Research, External Reviewer, 2019-present
Committee for Drosophilia Research & Screening Center, Executive Advisory Committee, 2020-present
NCATS Scientific Review, Ad Hoc, 2020
Pharmacology Graduate Group, University of Pennsylvania, 2020-present
Preclinical Therapeutic In Vitro Expert Panel for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), 2020-present
Provost Leadership Academy, University of Pennsylvania, 2020-present
Society for Laboratory Automation and Screening (SLAS), Organizer for Precision Medicine, 2021
American Association of Immunologists (AAI), Abstract Programming Chair, 2022-present
DMM 2023 Meeting London, “Infectious Diseases and Therapies: Insights from Host-Pathogen Evolution,” 2022
RNA Society, RNA 2022 Session Chair, 2022-present
Scialog, Facilitator, “Mitigating Zoonotic Threats,” 2022-present
Web Links
Selected Publications
The RNA helicase DDX39A binds a conserved structure in chikungunya virus RNA to control infection
Tapescu I, Taschuk F, Pokharel SM, Zginnyk O, Ferretti M, Bailer PF, Whig K, Madden EA, Heise MT, Schultz DC, Cherry S. Mol Cell 83(22):4174-4189.e7, Nov 2023. doi: 10.1016/j.molcel.2023.10.008. Epub 2023 Nov 9. PMID: 37949067; PMCID: PMC10722560.
Serotonin reduction in post-acute sequelae of viral infection
Wong AC, Devason AS, Umana IC, Cox TO, Dohnalová L, Litichevskiy L, Perla J, Lundgren P, Etwebi Z, Izzo LT, Kim J, Tetlak M, Descamps HC, Park SL, Wisser S, McKnight AD, Pardy RD, Kim J, Blank N, Patel S, Thum K, Mason S, Beltra JC, Michieletto MF, Ngiow SF, Miller BM, Liou MJ, Madhu B, Dmitrieva-Posocco O, Huber AS, Hewins P, Petucci C, Chu CP, Baraniecki-Zwil G, Giron LB, Baxter AE, Greenplate AR, Kearns C, Montone K, Litzky LA, Feldman M, Henao-Mejia J, Striepen B, Ramage H, Jurado KA, Wellen KE, O'Doherty U, Abdel-Mohsen M, Landay AL, Keshavarzian A, Henrich TJ, Deeks SG, Peluso MJ, Meyer NJ, Wherry EJ, Abramoff BA, Cherry S, Thaiss CA, Levy M. Cell 186(22):4851-4867.e20, Oct 2023. doi: 10.1016/j.cell.2023.09.013. Epub 2023 Oct 16. PMID: 37848036.
Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development
Jordan R, Ford-Scheimer SL, Alarcon RM, Atala A, Borenstein JT, Brimacombe KR, Cherry S, Clevers H, Davis MI, Funnell SGP, Gehrke L, Griffith LG, Grossman AC, Hartung T, Ingber DE, Kleinstreuer NC, Kuo CJ, Lee EM, Mummery CL, Pickett TE, Ramani S, Rosado-Olivieri EA, Struble EB, Wan Z, Williams MS, Hall MD, Ferrer M, Markossian S. J Infect Dis 228(Suppl 5):S337-S354, Oct 2023. doi: 10.1093/infdis/jiad334. PMID: 37669225; PMCID: PMC10547463.
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Eimer W, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Iwasaki A, Izquierdo-Garcia D, Locci M, Mehandru S, Painter MM, Peluso MJ, Pretorius E, Price DA, Putrino D, Scheuermann RH, Tan GS, Tanzi RE, VanBrocklin HF, Yonker LM, Wherry EJ. Nat Immunol 24(10):1616-1627, Oct 2023. doi: 10.1038/s41590-023-01601-2. Epub 2023 Sep 4. Erratum in: Nat Immunol. 2023 Sep 18; PMID: 37667052.
Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus
Dittmar M, Whig K, Miller J, Kamalia B, Suppiah S, Perelygina L, Sullivan KE, Schultz DC, Cherry S. PNAS Nexus 2(9):pgad256, Aug 2023. doi: 10.1093/pnasnexus/pgad256. PMID: 37674858; PMCID: PMC10479830.
SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection
Li M, Ayyanathan K, Dittmar M, Miller J, Tapescu I, Lee JS, McGrath ME, Xue Y, Vashee S, Schultz DC, Frieman MB, Cherry S. mBio 14(4):e0119423, Aug 2023. doi: 10.1128/mbio.01194-23. Epub 2023 Jun 28. PMID: 37377442; PMCID: PMC10470815.
Protocol to assess RNA-RNA interactions in situ using an RNA-proximity ligation assay
Basavappa MG, Henao-Mejia J, Cherry S. STAR Protoc 3(4):101892, Dec 2022. doi: 10.1016/j.xpro.2022.101892. Epub 2022 Dec 1. PMID: 36595913; PMCID: PMC9722720.
The lncRNA ALPHA specifically targets chikungunya virus to control infection
Basavappa MG, Ferretti M, Dittmar M, Stoute J, Sullivan MC, Whig K, Shen H, Liu KF, Schultz DC, Beiting DP, Lynch KW, Henao-Mejia J, Cherry S. Mol Cell 82(19):3729-3744.e10, Oct 2022. doi: 10.1016/j.molcel.2022.08.030. Epub 2022 Sep 26. PMID: 36167073; PMCID: PMC10464526.
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
Schultz DC, Johnson RM, Ayyanathan K, Miller J, Whig K, Kamalia B, Dittmar M, Weston S, Hammond HL, Dillen C, Ardanuy J, Taylor L, Lee JS, Li M, Lee E, Shoffler C, Petucci C, Constant S, Ferrer M, Thaiss CA, Frieman MB, Cherry S. Nature 604(7904):134-140, Apr 2022. doi: 10.1038/s41586-022-04482-x. Epub 2022 Feb 7. PMID: 35130559; PMCID: PMC10377386.
Orally acquired cyclic dinucleotides drive dSTING-dependent antiviral immunity in enterocytes
Segrist E, Dittmar M, Gold B, Cherry S. Cell Rep 37(13):110150, Dec 2021. doi: 10.1016/j.celrep.2021.110150. PMID: 34965418; PMCID: PMC8771144.